Keyphrases
Cutaneous Squamous Cell Carcinoma (cSCC)
100%
Pembrolizumab
100%
Complete Response
50%
Advanced Cutaneous Squamous Cell Carcinoma
50%
Antitumor Activity
33%
Objective Response Rate
33%
Clinical Benefit Rate
33%
Non-progression
33%
Poor Prognosis
16%
Stable Disease
16%
Overall Survival
16%
Adverse Events
16%
Safety Activity
16%
Progressive Disease
16%
Partial Response
16%
Duration of Response
16%
Progression-free Survival
16%
Follow-up Time
16%
Patient Demographics
16%
Clinical Trials
16%
Treatment-related Adverse Events
16%
Safety Profile
16%
Subgroup Analysis
16%
Trial Registration
16%
Activity Profile
16%
Rare Cancer
16%
PD-L1 Expression
16%
PD-1 Inhibitor
16%
L1 Axis
16%
Safety Objective
16%
Medicine and Dentistry
Skin Carcinoma
100%
Pembrolizumab
100%
Adverse Event
33%
Antineoplastic Activity
33%
Cancer
16%
Diseases
16%
Recurrent Disease
16%
Clinical Trial
16%
Overall Survival
16%
Progressive Disease
16%
Progression Free Survival
16%
Patient Population
16%
Subgroup Analysis
16%
Programmed Death-Ligand 1
16%
Pharmacology, Toxicology and Pharmaceutical Science
Skin Carcinoma
100%
Pembrolizumab
100%
Diseases
33%
Antitumor Activity
33%
Adverse Event
33%
Overall Survival
16%
Recurrent Disease
16%
Clinical Trial
16%
Progression Free Survival
16%
Immunology and Microbiology
Squamous Cell
100%
Pembrolizumab
100%
Antineoplastic Activity
33%
Overall Survival
16%
Programmed Death-Ligand 1
16%
Progression Free Survival
16%